Document:

Letter of Agreement and Product Loan Agreement

 Exhibit 10.30 
 

 
 an Applera Corporation Business 
 Legal Department 
 850 Lincoln Centre Drive 
 Foster City. CA 94404 U S A 
 www.appliedbiosystems.com 
 T 650 570 6667 T 800 874 9868 
 F 650 638 6071 F
650 638 6677 
 January 5, 2006 
 Mr. Robert Giles 
 Orchid Cellmark Inc. 
 13988 Diplomat Drive, #100 
 Farmers Branch, Texas 75324 
  

	Re:	Letter Agreement and Product Loan Agreement 

 Dear Bob: 

I am pleased on behalf of Applera Corporation, through its Applied Biosystems Group (“AB”), to offer the following **** to Orchid Cellmark
(“Cellmark”), subject to the conditions stated herein. 
 Cellmark agrees to place a purchase order with AB ****************. Under such purchase
order, subject to the further terms and conditions contained in this Letter Agreement, Cellmark agrees ***********************************************. The determination as to whether Cellmark has *******************. 
 As part of this offer, AB will: 
  

	 	•	 	*************************, which loan shall be subject to this Agreement and the Product Loan Agreement, a form of which is attached herein as Appendix B and which Cellmark will enter with AB prior to the instrument delivery to Cellmark; and 

  

	 	•	 	at no additional cost, provide Cellmark with: 

 **************** 
 ********************* 
 ******************** 
 ***************** 
 The above offer is further subject to the following: 
 AB shall deliver products purchased hereunder, and Cellmark agrees to
accept such delivery, in accordance with the annual schedule described on Appendix A. 
  

	*	THE REGISTRANT HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934.

 AB shall review Cellmark’s purchases quarterly, and if spending levels are not on track to meet annual Minimum
Commitment, AB may request return of the loaned instrument set forth above, and upon such request, Cellmark agrees to return to AB such loaned instrument following AB’s return instructions, AB may reduce the discounts for Cellmark’s future
purchases of the Products set forth on the attached Appendix A, and terminate the licenses for the GeneMapper software. Notwithstanding anything to the contrary contained in this Letter Agreement, the AB Terms of Sale (as defined) or the purchase
order, AB acknowledges that its sole remedy for the failure of Cellmark to meet the Minimum Commitment at any time shall be the rights of AB set forth in the previous sentence, and Cellmark shall have no other obligations or liabilities to AB as a
result of such failure. 
 All purchases of Products hereunder by Cellmark from AB will be solely subject to and governed by Applied Biosystems General Terms
and Conditions of Sale (“AB Terms of Sale”) attached herewith as Appendix C. In the event of any conflict between or among the provisions of the AB Terms of Sale, the purchase order and this Letter Agreement, the provisions of this
Letter Agreement shall govern. Any preprinted, or any inconsistent or additional, terms on quotations, purchase orders, invoices or other forms or documents shall have no force or effect. 
 This Letter Agreement shall be effective for *************; provided, that either party may terminate this Letter Agreement at any time, with or without cause, by giving
a written notice to the other party, at least sixty (60) days before the termination is to be effective. Provided further, that either party may terminate this Letter Agreement immediately by giving a written notice to the other party in the
event that the other party (a) becomes insolvent; (b) makes an assignment for the benefit of creditors; (c) files a petition in bankruptcy, or has filed against it a petition in bankruptcy which is not dismissed within ninety
(90) days; (d) has a receiver appointed for its assets; or (e) is dissolved or liquidated (collectively, “Insolvency Events”). 
 In
the event that Cellmark terminates this Letter Agreement before ********, except due to an uncured material breach by AB of this Letter Agreement or the AB Terms of Sale, or if AB terminates this Letter Agreement before ******** due to an uncured
material breach by Cellmark of this Letter Agreement or the AB Terms of Sale or Cellmark undergoing any Insolvency Events, Cellmark shall *****************************************************. Anything in this Letter Agreement, the AB Terms of Sale
or the purchase order to the contrary notwithstanding, in the event of any termination of this Letter Agreement for any reason, AB acknowledges that Cellmark’s sole liabilities and obligations shall be those specifically provided in this
paragraph and Cellmark shall have no other liabilities or obligations to AB. 
 In the event Cellmark terminates due to an uncured material breach by AB or
AB terminates this Letter Agreement without cause, upon request by AB, Cellmark shall ******************************************. Anything in this Letter Agreement, the AB Terms of Sale or the purchase order to the contrary notwithstanding, Cellmark
acknowledges that AB’s sole liabilities and obligations shall be those specifically provided in the immediately preceding sentence and AB shall have no other liabilities or obligations to Cellmark. 
 For purposes hereof, an “uncured material breach” shall mean a material breach which is not cured within thirty (30) days after written notice by the
non-breaching party to the breaching party. 
  

	*	THE REGISTRANT HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934.

 Notwithstanding anything to the contrary herein, ****************** when this Letter Agreement is terminated for whatever
reason. 
 ***********************. 
 As soon as we receive the
signed copy of this Letter Agreement, I will contact you to find out which instrument you would like to get on loan to Cellmark and I will duly prepare the Product Loan Agreement for execution. We will deliver your chosen loaned instrument within 30
days after we receive the signed Product Loan Agreement or within a reasonably time thereafter. 
 This Letter Agreement may only be amended by mutual
written agreement of the Parties. 
 If you accept this offer subject to the conditions set forth herein, please indicate
your agreement by signing below. 
  

	
	 Very truly yours,

	
	   
	 Danny Hall

	 Applied Biosystems

	 HID Account Manager

 I accept the above offer and agree to all the terms set forth herein: 
 Orchid Cellmark Inc. 

			
		
	 By:   
	 	  
		 	 Robert Giles

		 	 Executive Director

  

	*	THE REGISTRANT HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934.

 APPENDIX A 
  

											
	*	  	 	  	 	  	 	  	 	  	 
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	
	 *
	  		  		  		  		  	

 * Confidential treatment has been requested. 

											
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	
	*	  		  		  		  		  	

 * Confidential treatment has been requested. 

 APPENDIX B 
 PRODUCT LOAN AGREEMENT 
 Parties and addresses 
  

			
	Name	  	Applera Corporation, acting through its Applied Biosystems Group (“Applied Biosystems”)
	Address	  	850 Lincoln Center Drive, Foster City, CA 94404
	Fax	  	650-638-6610, Attn: Demonstration Program Manager
		
	Customer Name	  	Orchid Cellmark
		  	(“Customer”)
	Address	  	2600 Stemmons Freeway Suite 133
		  	Dallas Texas 75207
	Customer Contact	  	Person Mr. Robert Giles
	Fax
No.                                       
                                        
 

 Loaned Product (Part number and Model Name) 
  

 Loaned Product Location (if different than
Customer address provided above) 
  

  

 Applied Biosystems Sales Representative
                                        
                                        
                                        
                         
  

	**************	

 Customer’s use and possession of the Loaned Product shall be
subject to and governed exclusively by this Loaned Product Agreement, including the attached Loaned Product Terms and Conditions By signing this Agreement, Customer agrees to this Loaned Product Agreement, including the Loaned Product Terms and
Conditions attached. 
 Contact your Applied Biosystems representative if you wish to purchase the Loaned Product. 
  

									
	CUSTOMER	 		 	APPLERA CORPORATION, acting through its Applied Biosystems group
					
	 By:
	 	  	 		 	 By:
	 	  
	 Name:
	 	  	 		 	 Name:
	 	  
	 Title:
	 	  	 		 	 Title:
	 	  

 [For AB internal use: Serial Number(s) of unit(s) assigned to Customer:
                            ] 
  

			
	Approved for Signature
		
	by	 	 Jorge C. Barreno

	date	 	 1/11/06

	
	Applied Biosystems Group Legal Department

  

	*	Confidential treatment has been requested. 

 LOANED PRODUCT TERMS AND CONDITIONS 
 1. Delivery. At no cost to Customer, Applied Biosystems (“AB”) will deliver the Loaned Product to Customer on a mutually agreed date or as soon as reasonably feasible thereafter for Customer to use
during the Loan Period. 
 2. Title to Loaned Product. All right, title and interest in and to the Loaned Product shall remain with AB unless
and until Customer purchases the Loaned Product. 
 3. Technical and Service Support. During the Loan Period, at its discretion and at no
charge to Customer, AB may provide Customer with reasonable technical support and repair and maintenance service for the Loaned Product 
 4.
Customer’s Duties. After receipt of the Loaned Product until Customer obtains title to the Loaned Product or returns it to AB, Customer shall: (i) not transfer the Loaned Product from the Product Location specified above without the
prior written consent of AB; (ii) keep the Loaned Product free of all security interests, liens and other encumbrances; (iii) exercise due and proper care in the operation, use and maintenance of the Loaned Product and keep the Loaned
Product in good operating order, repair and condition; (iv) be solely responsible and liable for, and bear, all risk of, and pay or reimburse AB for all costs arising from, theft or other loss of, or destruction or damage to, the Loaned Product
from any and every cause whatsoever, from delivery to Customer until returned to AB; (v) permit AB access to Customer’s premises to inspect the Loaned Product and to permit AB to provide Customer with technical support or maintenance or
repair service on the Loaned Product, upon reasonable advance notice and subject to Customer’s reasonable confidentiality, security and health and safety requirements; and (vi) insure the Loaned Product against loss, theft, and damage. If
requested, Customer will furnish AB with a certificate of insurance evidencing such insurance coverage. 
 5. Return of Loaned Product.
Promptly after termination for whatever reason of this Agreement, or if Customer does not elect to purchase the Loaned Product before the end of the Loan Period promptly after the end of the Loan Period, at AB’s cost and in compliance with
reasonable instructions by AB (which may include returning a Certificate of Decontamination to AB if requested by AB), Customer shall return the Loaned Product to AB or permit AB to pick up the Loaned Product, at AB’s election Prior to
returning the Loaned Product, Customer will obtain from AB a return authorization number. Prior to return, Customer will fully clean the Loaned Product and decontaminate it of radioactive, biological, toxic and other dangerous or hazardous materials
or substances. 
 6. Label License. Customer shall use the Loaned Product in accordance with any applicable patent label license.

 7. Warranty Disclaimers. PRIOR TO ANY PURCHASE BY CUSTOMER OF THE LOANED PRODUCT, AND UNTIL SUCH PURCHASE, THE LOANED PRODUCT IS DELIVERED TO
CUSTOMER “AS IS,” WITHOUT WARRANTY OF ANY KIND, NATURE OR DESCRIPTION, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 8. LIMITATION OF LIABILITY. IN NO EVENT SHALL APPLIED BIOSYSTEMS BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE, OR ON ANY OTHER BASIS, FOR
SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES, WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT APPLIED BIOSYSTEMS IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF THE POSSESSION OR USE OF THE LOANED PRODUCT,
ANY INJURY OF DAMAGE CAUSED BY THE LOANED PRODUCT, OR OTHERWISE ARISING OUT OF THIS AGREEMENT OR FAILURE TO PERFORM OR BREACH OF THIS AGREEMENT. 
 9. Term; Termination. The Term of this Agreement and the Loan Period is co-terminus with the period the Letter Agreement is in effect. This Agreement may be terminated pursuant to the Letter Agreement to which this
Agreement is attached. 

 APPENDIX C 
 These Terms and Conditions of Sale (“Terms”) shall govern all orders for and purchases of products and services from Applied Biosystems (“AB”), unless other terms are specifically designated by AB to apply to a specific
product or service (See SOLE TERMS, INCONSISTENCIES, ORDER OF PRECEDENCE, below). 
 1. PRICE. The price for any product or service
(hereinafter “Product”) shall be the price stated in AB’s Quotation for Product (“AB’s Quotation”) AB’s Quotations are valid for 30 days unless otherwise stated in AB’s Quotation. If the price is stated by
reference to a published price list, then the price shall be the published price in effect at the time AB receives buyer’s purchase order. Prices stated are exclusive of all taxes, fees, licenses, duties or levies (“Taxes”) and,
unless otherwise stated in AB’s Quotation, transportation charges, freight and insurance. All Taxes related to Product shall be paid by buyer (other than taxes assessed against AB’s net income), or in lieu thereof, buyer shall provide a
tax exemption certificate acceptable to the relevant taxing authorities. Taxes and other charges payable by buyer may be billed as separate items on AB’s invoice. 
 2. PAYMENT TERMS; COLLECTION COSTS; SECURITY TERMS. Payment terms are net 30 days from date of AB’s invoice to buyer. If AB deems a customer to have become uncreditworthy, AB reserves the
right to require alternative payment terms, including without limitation sight draft, letter of credit, or payment in advance. Payment for partial shipments shall be based on unit or prorated prices, and payment for partial installation(s) shall be
based on percentage of completion of installation. If payment is not received by the due date, AB may assess and buyer agrees to pay a late payment charge at the rate of 1% per month (12% per year) or the maximum legal rate, whichever is less,
of the amount due from the due date to the date of payment. If AB retains a collection agency and/or attorney to collect unpaid amounts, AB may invoice buyer for, and buyer will pay, all costs of collection, including without limitation reasonable
attorneys fees Buyer hereby grants to AB and AB reserves a purchase money security interest in Product purchased hereunder, and in any proceeds thereof, for all amounts owing to AB for or related to such Product. Upon request by AB, buyer shall sign
any reasonable documents required for AB to perfect such security interest. Payment in full of all amounts owed for and related to such Product shall release the security interest on the Product. 
 3. CREDIT TERMS. AB may, at any time and in its sole discretion, limit or cancel the credit of buyer as to time and amount, suspend shipments, demand
payment in cash before delivery of Product, or demand other assurances of buyer’s performance. If within 30 days buyer fails to agree and comply with the different terms of payment demanded, or fails to give adequate assurances of performance,
AB may, without prejudice to any other right or remedy AB may have: (1) by notice to buyer, treat such failure or refusal as a repudiation by buyer of that portion of buyer’s order not then fully performed, whereupon AB may cancel all
further deliveries, and any amounts unpaid for non-cancelled Product shall immediately become due and payable; or (2) make shipments under reservation of a security interest and demand payment against tender of title documents. 
 4. DELIVERY; TITLE AND RISK OF LOSS. AB will use reasonable efforts to ship Product within a reasonable time after ordered, or, if a shipment date
is indicated in AB’s Quotation or otherwise agreed upon in writing by an authorized representative of AB, on or before such date. AB may make delivery in installments, and each installment shall be deemed to be a separate sale AB may render a
separate invoice for each installment, which invoice shall be paid without regard to prior or subsequent installments. Unless indicated otherwise in AB’s Quotation, title and risk of loss with respect to all Products except Software, and risk
of loss with respect to Software, shall pass from AB to buyer upon delivery. Delivery shall be deemed made upon transfer of possession to a common or other third party carrier at AB’s facility. 
 5. CANCELLATION AND DEFERRAL. A PURCHASE ORDER IS NOT SUBJECT TO CANCELLATION BY BUYER. However, unless otherwise stated in AB’s quotation,
buyer may defer the shipment date one time for up to 

 60 days for instruments and other hardware, and 30 days for reagents, consumables and other tangible products, by giving
written notice to AB at least 30 days before the scheduled shipment date for instruments and other hardware, and at least 10 days before the scheduled shipment date for other products. 
 6. REJECTION. Any claims for damaged, missing or defective Product must be reported in writing by buyer within 15 days from the date of receipt of Product. In addition, buyer must promptly return
a rejected Product to AB, C O D, accompanied by a valid return authorization number obtained from AB. AB may refuse any Product not timely rejected or sought to be returned without a valid return authorization number. For any valid claim timely
made, AB, at its option, may repair Product or replace Product with an identical or substantially similar product, THESE ARE BUYER’S SOLE AND EXCLUSIVE REMEDIES FOR DAMAGED OR MISSING PRODUCT, AND, EXCEPT FOR EXPRESS WARRANTY RIGHTS, FOR
DEFECTIVE PRODUCT. 
 7. LIMITED WARRANTY. AB makes only those warranties with respect to Product expressly identified as
“warranties” and set forth in AB’s current operating manual or catalog, or in a specific written warranty included with and covering Product, if any ANY PRODUCT NOT COVERED BY A WRITTEN WARRANTY IS SOLD “AS IS.” If buyer
furnishes specifications to AB, buyer agrees to defend, indemnify and hold AB harmless against any claim that arises out of AB’s compliance with such specifications. Any description of Product recited in AB’s Quotation is for the sole
purpose of identifying Product, and any such description is not part of any contract between AB and buyer and does not constitute a warranty that Product shall conform to that description. Any sample or model used in connection with AB’s
Quotation is for illustrative purposes only, and is not part of any contract between AB and buyer and does not constitute a warranty that Product will conform to the sample or model, No affirmation of fact or promise made by AB, whether or not in
AB’s Quotation, shall constitute a warranty that Product will conform to the affirmation or promise. THE WARRANTIES IDENTIFIED IN THE FIRST SENTENCE OF THIS PARAGRAPH ARE AB’S SOLE AND EXCLUSIVE WARRANTIES WITH RESPECT TO PRODUCT AND
ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, ALL OF WHICH OTHER WARRANTIES ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WHETHER ARISING FROM A STATUTE OR OTHERWISE
IN LAW OR FROM A COURSE OF DEALING OR USAGE OF TRADE. 
 8. INTELLECTUAL PROPERTY INDEMNITY. Subject to the restrictions set forth
in this Article and provided buyer complies with its obligations in this Article, AB agrees to defend buyer, and indemnify buyer from and against any infringement damages finally awarded, in any legal action or proceeding brought by a third party
against buyer to the extent that such action is based on a claim that the manufacture and sale of Product by AB infringes any United States or foreign patent, copyright, trademark or other intellectual property right of such third party. 

Buyer’s Obligations. Buyer must notify AB in writing of any claim for which it may seek defense and indemnity from AB hereunder promptly after
becoming aware of such claim, and shall cooperate with and provide all reasonable assistance to AB, at AB’s expense, in the defense or settlement of such claim. AB shall have sole authority to defend and/or settle any claim under this Article.

 Remedy for infringement, Rights of AB, Exceptions. If any Product or any portion thereof is subject to a suit or other legal proceeding claiming
that the Product infringes a third party’s intellectual property right, or in AB’s opinion is (are) likely to become subject of such a claim, AB shall, at its option, have the right to either: (a) procure for buyer the right to
continue using the Product; or (b) replace or modify the Product so that it becomes non-infringing; or (c) require buyer to return the Product and upon return, refund to buyer the price actually paid by buyer for the Product, less a
reasonable amount for use, damage or obsolescence; or (d) substitute for the infringing Product other suitable, non-infringing products. AB shall have no liability or obligation hereunder for any infringement based upon: (i) the use of
Product in combination with any product not provided by AB or intended for use with Product, or based upon any modification to Product made by buyer or a third party, if such claim would not 

 have occurred but for such combination or modification; or (ii) any modification, marking or branding applied to
Product by AB at the request of the buyer 
 THE FOREGOING STATES THE ENTIRE LIABILITY OF AB, AND THE EXCLUSIVE REMEDY OF BUYER, FOR ANY INFRINGEMENT OR
CLAIMED INFRINGEMENT OF PATENT, COPYRIGHT, TRADE SECRET OR ANY OTHER INTELLECTUAL PROPERTY RIGHT BY PRODUCT OR ANY PART THEREOF OR USE THEREOF. 
 9.
COMPLIANCE WITH LAWS, VALIDATION. Without limiting the generality of the paragraph above entitled “LIMITED WARRANTY,” unless otherwise expressly stated in writing by AB, no claim or representation is made or intended (i) as to any
clinical use of any Product (whether diagnostic, prognostic, therapeutic, blood banking or any other clinical use), (ii) that any Product has been cleared, approved, registered or otherwise qualified (collectively, “Approval”) by AB
with any regulatory agency for use in any clinical procedure or for other use requiring compliance with any federal, state, European or any other governmental agency or regulatory body regulating diagnostic, therapeutic, blood or other clinical
products, medical devices or similar products (collectively, “Regulatory Laws”), (iii) that any Product will satisfy the requirements of any governmental body or other organization, including, but not limited to, the United States
Food and Drug Administration or the International Organization for Standardization, or (iv) that any Product or its performance is suitable or has been validated for any specific use or application. Products should not be used for any purpose
that would require Approval unless proper Approval is obtained, or, in the case of use in diagnostic laboratory systems and then only to the extent permitted by law, the laboratory has validated its complete system as required by the Clinical
Laboratory Improvements Act of 1988, as amended, in the United States or equivalents in other countries. Buyer agrees that if it elects to use Products for a purpose that would subject buyer, its customers, or any Products to the jurisdiction of
Regulatory Laws or other applicable law, buyer shall be solely responsible for obtaining any required Approvals or other approvals and otherwise ensuring that its use of any Products complies with such laws. Buyer agrees that it is the buyer’s
responsibility, and not AB’s, to validate the performance of Products for any specific use or application and to ensure that Products meet applicable regulatory, certification, validation or its other requirements, since the use and performance
characteristics of Products have not been validated by AB for any specific use or application, except as may be otherwise expressly set forth by AB in writing. Products should be used in strict accordance with applicable instructions, warnings and
other information in user manuals and other Product documentation. 
 10. FORCE MAJEURE. AB shall not be liable for any delay or failure of
performance, including without limitation failure to deliver or failure to install, where such delay or failure arises or results from any cause beyond AB’s control, including, but not limited to, flood, unusually severe weather, earthquake or
other act of God, power loss, strike, boycott, or other labor disputes, embargo, governmental regulation or an inability or delay in obtaining materials. In the event of any such delay or failure of performance, AB shall have such additional time
within which to perform its obligations hereunder as may be reasonably necessary under the circumstances; and AB shall also have the right, to the extent necessary in AB’s reasonable judgment, to apportion Product then available for delivery
fairly among its various customers in such manner as AB may consider equitable. 
 11. LIMITATION OF LIABILITY. IN NO EVENT SHALL AB BE LIABLE,
WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES SUSTAINED BY BUYER OR ANY OTHER PERSON OR ENTITY ARISING OUT OF AB’S PERFORMANCE OR
FAILURE TO PERFORM ITS OBLIGATIONS RELATING TO THE PURCHASE OF PRODUCTS OR PERFORMANCE OF SERVICES, THE POSSESSION OR USE OF ANY PRODUCT, OR THE PERFORMANCE BY AB OF ANY SERVICES, WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT AB IS ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES ARISING FROM OR RELATED TO LOSS OF USE, LOSS OF DATA, DOWNTIME, OR FOR LOSS OF REVENUE, PROFITS, GOODWILL, OR BUSINESS OR OTHER FINANCIAL LOSS. 

 12. SOLE TERMS; INCONSISTENCIES; ORDER OF PRECEDENCE. These Terms, together with AB’s Quotation, any
applicable label license or other written conditions of use and any other terms and conditions expressly agreed to in writing by an authorized representative of AB “(collectively, “AB’s Terms”), constitute the complete, exclusive
and entire agreement between AB and buyer with respect to purchases of Product (unless other terms and conditions are expressly designated to be applicable by AB in writing), and AB’s offer to sell is expressly limited to such terms. Such terms
shall take precedence over and supercede and replace all prior or contemporaneous understandings or agreements, written or oral, and any of buyer’s additional or different terms and conditions, which are hereby rejected and shall be void.
Buyers submission of a purchase order or other instrument regarding the purchase of Product in response to AB’s Quotation or any other AB document that includes or incorporates these Terms shall be deemed acceptance of these Terms to the
exclusion of any other terms and conditions appearing in or referenced in such purchase order or other instrument, which are hereby deemed to be material alterations and notice of objection to which is hereby given, notwithstanding anything
contained to the contrary in such purchase order or other instrument or elsewhere. Any acceptance by AB of any offer of buyer is expressly conditioned on buyer’s assent to and acceptance of AB’s Terms to the extent they are additional or
different terms. Except as otherwise provided in these Terms, in the event of an inconsistency between these Terms and the terms appearing on AB’s Quotation or other agreement signed by an authorized representative of AB, the terms appearing on
AB’s Quotation or such other agreement shall supersede and take precedence over the inconsistent provision(s) of these Terms, and all other provisions of these Terms shall remain in full force and effect Nothing in these Terms shall be deemed
or construed to limit AB’s rights to enforce its patent or other intellectual property rights, including without limitation as to any use of Product beyond that granted under any patent or other intellectual property label license applicable to
Products. 
 13. CHOICE OF LAW. Any contract between AB and buyer relating to Product, including these Terms, and any disputes relating
thereto, shall be governed by and construed in accordance with the laws of the State of California, U.S.A., excluding both its choice of law provisions and the UN Convention on Contracts for the International Sale of Goods. 
 14. EXPORT CONTROLS. Buyer agrees that it will not export or transfer Product for re-export in violation of any United States laws or regulations, or to any
denied or prohibited person, entity, or embargoed country in violation of such laws or regulations. 
 15. MISCELLANEOUS. No amendment of
AB’s Quotation or these Terms or modification thereof shall be binding unless in writing and signed by a duly authorized representative of both AB and buyer, AB’s failure to exercise any rights hereunder shall not constitute or be deemed a
waiver or forfeiture of such rights or any other rights hereunder. Headings are included herein for convenience of reference only and shall not constitute a part of these Terms for any other purpose. If any provision of AB’s Terms shall be held
to be invalid or unenforceable for any reason, such provisions shall, to the extent of such invalidity or enforceability, be severed without in any way affecting the remainder of such provision or any other provision thereof, all of which shall
continue in full force and effect. 
 ADDITIONAL TERMS AND CONDITIONS OF SALE FOR OLIGONUCLEOTIDE PRODUCTS, INCLUDING SPECIAL TERMS TO
PROTECT CUSTOMER CONFIDENTIAL INFORMATION 
 THESE ADDITIONAL TERMS AND CONDITIONS FOR OLIGONUCLEOTIDE PRODUCTS, AS WELL AS ALL OF THE GENERAL TERMS AND
CONDITIONS OF SALE SET FORTH ABOVE, APPLY TO THE PURCHASE OF ALL APPLIED BIOSYSTEMS OLIGONUCLEOTIDE PRODUCTS, INCLUDING ASSAYS BY DESIGNSM, ASSAYS ON DEMANDTM AND CUSTOM OLIGONUCLEOTIDE PRODUCTS. 

 Using proprietary technology, AB designs and manufactures for sale, whether to order using customer specifications or as
off-the-shelf inventory generally available to customers, a variety of oligonucleotide products, including custom oligonucleotide sequences of both unlabeled/fluorescent-labeled primer pair sets and dual-labeled fluorescent probe/unlabeled primer pair combinations, for use in various genetic and related analytic assays, such as 5’ nuclease
detection assays. 
 AB’s oligonucleotide products are sold for research use only. All purchases of AB’s oligonucleotide products are subject to
all of the terms and conditions of these General Terms and Conditions of Sale, including these Additional Terms and Conditions of Sale for Oligonucleotide Products. 
  

	16.	DEFINITIONS 

 The following
definitions apply to these Additional Terms and Conditions of Sale for Oligonucleotide Products. 
 Assays-by-Design Kit means a 5’ nuclease
detection assay kit that is either: (a) an Assays-by-DesignSM Single Nucleotide Polymorphism (SNP) Genotyping
Service kit comprising two (2) Minor Groove Binder (MGB) probes and two (2) primers, or (b) an Assays-by-Design Gene Expression Service kit comprising one (1) MGB probe, or other dual labeled fluorescent probe, and two
(2) primers MGB probes are made available through exclusive license to Applied Biosystems from Epoch BioSciences, Inc. 
 Assays-by-Design
Sequence means the specifically targeted region of a genome specified by buyer for amplification by the AB primers and probes in an Assays-by-Design Kit. 
 Assays-On-Demand Kit means any of a large selection of Assays-on-DemandTM SNP Genotyping Products and/or Assays-on-Demand Gene Expression products containing primer and probe oligonucleotides that are available off-the-shelf for
purchase from AB. 
 Confidential Information of Buyer means the “Assays-By-Design Sequences” and the “Custom Oligo Sequences” (as
these terms are defined below) furnished by buyer to AB under this Agreement, and the facts that buyer placed orders for such sequences and that buyer ordered oligonucleotide products from AB containing such sequences. 
 Custom Kit means, collectively or individually as the context indicates, (a) an Assays-By-Design Kit, or (b) a Custom Oligo Synthesis Kit. 

Custom Oligo Sequence means the specific oligonucleotide sequence that is to be manufactured by AB, and related information supplied by buyer to AB, in
connection with a Custom Oligo Synthesis Kit order. 
 Custom Oligo Synthesis Kit means an assay kit manufactured by AB and containing one or more
fluorescent labeled (single or multiple labels) and/or unlabelled oligonucleotides, with the nucleotide arrangements thereof specified by buyer in an order (the “Custom Oligo Sequence,” as defined herein). 
 Kit means collectively or separately, as the context requires, (a) an Assays-By-Design Kit, (b) a Custom Oligo Synthesis Kit, and/or, (c) an
Assays-On-Demand Kit. 

 Synthesis means the design (where applicable) and manufacture by AB of Custom Kits for delivery to buyer pursuant
to this Agreement. 
 17. KITS. 
 Shipment of Kits.
AB will use reasonable commercial efforts to ship Kits ordered by buyer from AB in a timely manner. Assays-On-Demand Kits, if in stock at the time of the order, are generally available for shipment within two business days of receipt by AB of the
order. Assays-by-Design Kits and Custom Oligo Synthesis Kits are the product of AB’s research, design and manufacturing efforts and are made available for shipment promptly following completion of Synthesis. Buyer understands and agrees that
any proffered shipment/delivery date for Kits other than in-stock Assays-On-Demand Kits is approximate only and buyer has taken this into account when placing each order. 
 AB’s Evaluation of Custom Kit Orders. AB may decline the Synthesis, at any stage of the Synthesis process, of any Custom Kit ordered by buyer that AB, in it’s reasonable good faith judgment,
deems to be unsuitable or commercially impractical for Synthesis, whether on technological or other grounds. AB will give written notice to buyer within a reasonable time following its determination to decline Synthesis of a Custom Kit. Buyer shall
have no obligation to pay any fees for time and materials, or for any other expenses incurred by AB, in connection with any declined Custom Kit. All Custom Kit orders not declined by AB will be synthesized, must be paid for by buyer, and may not be
cancelled or changed by buyer without the express written permission of AB. Buyer understands and agrees that buyer’s obligation to pay fees for all Custom Kits that AB proceeds to Synthesize is firm and irrevocable, regardless of the number of
Custom Kits declined for Synthesis in a given order Accordingly, each purchase order for Custom Kits must be for the total amount charged for all Custom Kits ordered. The amount corresponding to the charges applicable to declined Synthesis will be
reflected in AB’s invoice for the order. 
 Primer and Probe Quantities in Custom Kits. The quantities of unlabelled oligonucleotides,
fluorescent-labeled oligonucleotides and/or MGB probes included in Kits are as set forth in AB’s current general product list or price list as published from time to time. If a particular Kit is not listed in an AB current product list or price
list, buyer may contact AB for such information. 
 Label License Kit Use Provisions. Buyer understands and agrees that its use of each Kit is
further regulated by and subject to the terms stated on the individual label license that accompanies each Kit, copies of which label licenses are available from AB. The placing by buyer of any Kit order is deemed an agreement by buyer to the terms
and conditions of the label license applicable to each Kit and buyer hereby acknowledges having had ample opportunity to review the pertinent label licenses in advance of placing buyer’s order. 
 18. APPLIED BIOSYSTEMS, REPRESENTATIONS, WARRANTIES AND LIMITATIONS OF LIABILITY. 
 With regard to oligonucleotide products provided by AB under this Agreement, AB warrants that it will make commercially reasonable efforts and employ standards that are at least consistent with those practiced by the
chemical manufacturing industry to produce Synthesis results that are scientifically accurate and valid according to the prevailing standards at the time and place of manufacture in the biotechnology industry, subject to the quality, timeliness and
accuracy of all information, whether Confidential Information or otherwise, and material that buyer furnishes to AB for purposes of executing the Synthesis. 

 EXCLUSIONS FROM WARRANTY. AB DOES NOT REPRESENT OR WARRANT THAT ANY KITS OR OTHER PRODUCTS SUPPLIED BY APPLIED
BIOSYSTEMS WILL AMPLIFY THE TARGET SEQUENCES, INCLUDING WITHOUT LIMITATION ANY ASSAYS-BY-DESIGN SEQUENCES SPECIFIED BY BUYER, IN ADDITION, AB DOES NOT MAKE AND EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY WITH RESPECT TO KITS OR OTHER
PRODUCTS SUPPLIED BY APPLIED BIOSYSTEMS, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITATION OF THE FOREGOING, BUYER AGREES THAT AB SHALL NOT BE RESPONSIBLE FOR ANY CONSEQUENCES ARISING
FROM THE FAILURE OF KITS TO AMPLIFY ANY SEQUENCES OR THE FAILURE TO BE ACCURATE OR CORRECT OF ANY DATA, SPECIFICATIONS, OR OTHER MATERIALS OR INFORMATION, INCLUDING WITHOUT LIMITATION BUYER’S CONFIDENTIAL INFORMATION, ASSAYS-BY-DESIGN SEQUENCES
AND CUSTOM OLIGO SEQUENCES (COLLECTIVELY, THE “CUSTOMER MATERIALS”) SUPPLIED BY BUYER IN CONNECTION WITH ANY AND ALL ORDERS PLACED WITH AB. 
 19. BUYER’S REPRESENTATIONS, WARRANTIES AND LIMITATIONS OF LIABILITY. 
 By submitting an order, buyer represents, warrants and agrees:

  

	 	1.	That buyer will provide AB with all information known to buyer regarding biological, radiological, and/or chemical hazards associated with the handling, exposure to or other use of
any Customer Materials supplied to AB by buyer; and 

  

	 	2.	That buyer has the right to cause the sequences that buyer has requested AB to manufacture to be manufactured by AB and sold to buyer, that such sequences and the manufacture and
sale thereof to buyer will not infringe the intellectual property rights, including without limitation patent, copyright, trademark, and trade secrets, of any third party anywhere in the world (provided that the foregoing shall not be deemed a
representation or warranty with respect to methods of manufacture employed by AB), and that the Customer Materials buyer furnishes to AB will not infringe any such intellectual property rights; and 

  

	 	3.	That the Kits and components thereof sold to buyer shall be for buyer’s own internal research and development use only, shall be used only as permitted under the label licenses
associated with each Kit, and shall not be resold or otherwise transferred or conveyed to any third party without the express written permission of AB. 

 20. CONFIDENTIAL INFORMATION OF BUYER. 
 AB agrees that for seven (7) years after the disclosure by buyer to AB
of Confidential Information of Buyer, AB shall not disclose such Confidential information of Buyer to any third party and will use at least the same degree of care as it uses to protect its own confidential information of a like nature, but in no
event less than a reasonable degree of care, to prevent the disclosure of such Confidential Information of Buyer to any third party. This undertaking of confidentiality shall not apply to, and AB shall have no obligations under this paragraph with
respect to, any Confidential Information of Buyer that (a) was in AB’s possession before receipt from buyer, (b) is or becomes a matter of public knowledge or part of the public domain through no fault of AB, (c) is rightfully
received by AB from a third party that was not obliged to keep such information confidential, (d) is developed by AB without reference to Confidential Information of Buyer, or (e) is disclosed by AB with buyer’s prior written
approval. Notwithstanding the foregoing, AB may disclose Confidential Information of Buyer to the extent required to comply with governmental regulations and other applicable laws or to respond to subpoena or other compulsory legal process, provided
in all cases that AB takes reasonable and lawful actions to avoid or minimize the extent of such disclosure and notifies buyer in writing as far in advance of the date of disclosure as is reasonably feasible so that buyer to the extent feasible will
have an opportunity to seek to prevent or limit disclosure 

 21. INTELLECTUAL PROPERTY RIGHTS. 
 Any inventions (patentable or otherwise), discoveries, developments, improvements, information, data, compounds, formulae, know-how or other results that are conceived, developed, reduced to practice, or generated by
AB or jointly by buyer and AB and that relate and/or apply to the processes and methods used in or related to the Synthesis of Kits or otherwise in connection with designing and/or manufacturing Kits and associated primers and probes shall be and
remain the sole and exclusive intellectual property of AB. Buyer will take all reasonable and appropriate steps, upon the request and at the expense of AB, to assist AB to secure, evidence and record its rights in such intellectual property.

 22. NO GRANT OF RIGHTS. 
 Nothing in this Agreement
shall be interpreted expressly or impliedly as: 
 (a) granting either buyer or AB any license or other rights except as expressly set out in this Agreement,
or granting either party the right to be supplied with, or to manufacture or to have manufactured, any quantities of Kits and/or any components thereof beyond those ordered in accordance with the terms and conditions of this Agreement; 

(b) granting buyer the right to resell or convey in any manner the Kits or any components thereof to any third party anywhere in the world.Form of Note

 Exhibit 4.1 
 THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE OF A DEPOSITORY. THIS NOTE IS NOT EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A
PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A
NOMINEE OF THE DEPOSITORY TO THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 Unless this Note is presented by an authorized representative of The Depository Trust Company, a New York corporation (55 Water Street, New York, New York) (“DTC”), to the Corporation or its agent for registration of transfer,
exchange or payment, and this Note is registered in the name of Cede & Co. or such other name as requested by an authorized representative of DTC, and unless any payment is made to Cede & Co., ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL since the registered owner hereof, Cede & Co., has an interest herein. 
 THIS NOTE IS
NOT A SAVINGS ACCOUNT OR A DEPOSIT, IS NOT AN OBLIGATION OF OR GUARANTEED BY ANY BANKING OR NONBANKING AFFILIATE OF BANK OF AMERICA CORPORATION, AND IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL AGENCY.

  

					
	 REGISTERED
	 		 	$92,000,000
			
	NUMBER     I-        	 		 	CUSIP 06050 MFS1

 BANK OF AMERICA CORPORATION 
 MEDIUM-TERM SENIOR NOTE, SERIES K 
 (Indexed Note) 
  

	 ̈	SEE THE ATTACHED PRINCIPAL REPAYMENT AMOUNT RIDER for a description of the PRINCIPAL REPAYMENT AMOUNT and its method of calculation. 

  

	x	SEE THE ATTACHED SUPPLEMENTAL REDEMPTION AMOUNT RIDER for a description of the SUPPLEMENTAL REDEMPTION AMOUNT and its method of calculation 

 ORIGINAL ISSUE DATE: May 26, 2006 
 MATURITY DATE: August 26, 2010

 CALCULATION AGENT: Banc of America Securities LLC (“BAS”) 
 ADDITIONAL TERMS: See Supplemental Redemption Amount Rider 
 MINIMUM DENOMINATIONS: $1,000 and whole multiples of $1,000. 
 BANK OF AMERICA CORPORATION, a Delaware corporation (the “Corporation,” which term includes any successor corporation under the Indenture
referred to on the reverse hereof), for value received, hereby promises to pay on the Maturity Date to CEDE & CO., as nominee for The Depository Trust Company, or its registered assigns, (i) the principal amount of NINETY TWO MILLION
DOLLARS ($92,000,000) and (ii) that supplemental redemption amount (the “Supplemental Redemption Amount”) calculated according to the terms of the attached Supplemental Redemption Amount Rider. 
 Any principal or Supplemental Redemption Amount not punctually paid or duly provided for shall be payable as provided in the Indenture. As used in this
Note, “Business Day” means any weekday that is not a legal holiday in New York, New York, Charlotte, North Carolina or any other place of payment of this Note and that is not a date on which banking institutions in those cities or any
other place of payment with respect to this Note are authorized or required by law or regulation to be closed. 

 The principal and Supplemental Redemption Amount on this Note are payable in immediately available funds
in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts at the office or agency of the Corporation designated as provided in the Indenture; provided,
however, that the principal and Supplemental Redemption Amount may be paid, at the option of the Corporation, by check mailed to the person entitled thereto at his address last appearing on the registry books of the Corporation relating to
the Notes. Notwithstanding the preceding sentence, payments of the principal and Supplemental Redemption Amount payable on the Maturity Date will be made by wire transfer of immediately available funds to a designated account maintained in the
United States upon (i) receipt of written notice by the Issuing and Paying Agent (as described on the reverse hereof) from the registered holder of this Note not less than one Business Day prior to the due date of such principal and
(ii) presentation of this Note to The Bank of New York, as Issuing and Paying Agent, 101 Barclay Street, New York, New York 10286 (the “Corporate Trust Office”). 
 For both this Note and Notes issued in certificated form, the payment of principal and any other amounts due on or after the Maturity Date will be made
only upon the presentation and surrender of such Note at the office of the Trustee or successor thereof, and with respect to this Note, in accordance with the procedures of DTC. 
 References herein to “U.S. dollars,” “U.S.$,” or “$” are to the coin or currency of the United States at the time of
payment is legal tender for the payment of public and private debts. 
 Reference is hereby made to the further provisions of this Note set
forth on the reverse hereof and on the attached Rider, which shall have the same effect as though fully set forth at this place. 
 Unless
the certificate of authentication hereon has been executed by the Trustee or an authenticating agent on behalf of the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any
purpose. 
  

 2 

 IN WITNESS WHEREOF, the Corporation has caused this Note to be duly executed, by manual or facsimile
signature, under its corporate seal or a facsimile thereof. 
  

									
		 		 		 	BANK OF AMERICA CORPORATION
					
		 		 		 	By:	  	  

	[SEAL]	 		 		 	Title:	  	Senior Vice President
	ATTEST:	 		 		 		  	

  

									
					
	By:	 	  
	 		 		  	
	Title:	 	Assistant Secretary	 		 		  	

  

 3 

 Certificate of Authentication 
 This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 
 Dated: May 26, 2006 
  

			
	 THE BANK OF NEW YORK,
 as
Trustee

		
	By:	 	  

		 	Authorized Signatory

  

 4 

 [Reverse of Note] 
 BANK OF AMERICA CORPORATION 
 MEDIUM-TERM SENIOR NOTE, SERIES K 
 (Indexed Note) 
 SECTION 1. General.
This Note is one of a duly authorized series of Securities of the Corporation unlimited in aggregate principal amount (herein called the “Notes”) issued and to be issued under an Indenture dated as of January 1, 1995 (herein called
the “Indenture”), between the Corporation (successor in interest to NationsBank Corporation) and The Bank of New York, as Trustee (successor in interest to U.S. Bank Trust National Association, successor trustee to BankAmerica National
Trust Company, herein called the “Trustee,” which term includes any successor trustee under the Indenture), as supplemented by a First Supplemental Indenture dated as of September 18, 1998, a Second Supplemental Indenture dated as of
May 7, 2001, a Third Supplemental Indenture dated as of July 28, 2004, and a Fourth Supplemental Indenture dated as of April 28, 2006, to which Indenture and all indentures supplemental thereto reference is hereby made for a statement
of the respective rights thereunder of the Corporation, the Trustee, and the holders of the Notes, and the terms upon which the Notes are, and are to be, authenticated and delivered. This Note is also one of the Notes designated as the
Corporation’s Senior Medium-Term Notes, Series K, initially limited in aggregate principal amount to $10,000,000,000. The Trustee initially shall act as Security Registrar, Transfer Agent, and Issuing and Paying Agent in connection with the
Notes. The Notes may bear different dates, mature at different times, bear interest at different rates, and vary in such other ways as are provided in the Indenture. 
 SECTION 2. No Sinking Fund. This Note is not subject to any sinking fund. 
 SECTION 3.
Redemption. This Note is not redeemable prior to the Maturity Date. 
 SECTION 5. Defeasance. The provisions of Article
Fourteen of the Indenture do not apply to Securities of this Series. 
 SECTION 6. Events of Default. If an Event of Default (defined
in the Indenture as (a) the Corporation’s failure to pay the principal of (or premium, if any, on) the Notes; (b) the Corporation’s failure to pay interest on the Notes within 30 calendar days after the same becomes due;
(c) the Corporation’s breach of its other covenants contained in this Note or in the Indenture, which breach is not cured within 90 calendar days after written notice by the Trustee or the holders of at least 25% in outstanding principal
amount of all Securities issued under the Indenture and affected thereby; and (d) certain events involving the bankruptcy, insolvency or liquidation of the Corporation) shall occur with respect to the Notes, the principal of all the Notes may
be declared due and payable in the manner and with the effect provided in the Indenture. 
 SECTION 7. Modifications and Waivers. The
Indenture permits, with certain exceptions as therein provided, the amendment of the Indenture and the modification of the rights and obligations of the Corporation and the rights of the holders of the Notes under the Indenture at any time by the
Corporation with the consent of the holders of not less than 66 2/3% in aggregate principal amount of the Notes then outstanding and all other Securities then outstanding under 
  

 5 

 the Indenture and affected by such amendment and modification. The Indenture also contains provisions permitting the
holders of a majority in aggregate principal amount of the Notes then outstanding and all other Securities then outstanding under the Indenture and affected thereby, on behalf of the holders of all such Securities, to waive compliance by the
Corporation with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the holder of this Note shall be conclusive and binding upon such holder and upon all future
holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof whether or not notation of such consent or waiver is made upon this Note. 
 No recourse shall be had for the payment of the principal of, premium on (if any), or other amounts payable on this Note, or for any claim based hereon,
or otherwise in respect hereof, or based on or in respect of the Indenture or any indenture supplemental thereto, against any incorporator, stockholder, officer, or director, as such, past, present, or future, of the Corporation or any predecessor
or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for issue
hereof, expressly waived and released. 
 SECTION 8. Obligations Unconditional. No reference herein to the Indenture and no provision
of this Note or of the Indenture shall alter or impair the obligation of the Corporation, which is absolute and unconditional, to pay the principal of, premium (if any), and other amounts payable on this Note at the times, place and rate, and in the
coin or currency, herein prescribed. 
 SECTION 9. Authorized Denominations. The Notes are issuable only as registered Notes without
coupons, and unless otherwise set forth above, only in denominations of $1,000 and whole multiples of $1,000. As provided in the Indenture, and subject to certain limitations therein set forth, Notes are exchangeable for a like aggregate principal
amount of Notes of different authorized denominations, as requested by the holder surrendering the same. 
 SECTION 10. Registration of
Transfer. As provided in the Indenture and subject to certain limitations as therein set forth, the transfer of this Note is registrable in the register maintained by the Registrar, upon surrender of this Note for registration of transfer at the
office or agency of the Corporation designated by it pursuant to the Indenture, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Corporation and the Trustee or the Security Registrar requiring such
written instrument of transfer duly executed by, the registered holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes of this series, of authorized denominations and for the same aggregate principal amount,
will be issued to the designated transferee or transferees. 
 This Note is being issued by means of a book-entry system with no physical
distribution of certificates to be made except as provided in the Indenture. The book-entry system maintained by The Depository Trust Company (“DTC”) will evidence ownership of the Notes, with transfers of ownership effected on the records
of DTC and its participants pursuant to rules and procedures established by DTC and its participants. The Corporation will recognize Cede & Co., as nominee of DTC, while the registered holder of the Notes, as the owner of the Notes for all
purposes, including payment of principal and the Supplemental Redemption Amount, notices, 
  

 6 

 and voting. Transfer of principal and the Supplemental Redemption Amount to participants of DTC will be the
responsibility of DTC, and transfer of principal and the Supplemental Redemption Amount payable to beneficial owners of the Notes by participants of DTC will be the responsibility of such participants and other nominees of such beneficial owners. So
long as the book-entry system is in effect, the selection of any Notes to be redeemed will be determined by DTC pursuant to rules and procedures established by DTC and its participants. The Corporation will not be responsible or liable for such
transfers or payments or for maintaining, supervising, or reviewing the records maintained by DTC, its participants, or persons acting through such participants. 
 This Note may be exchanged in whole, but not in part, for security-printed certificated Notes, only if (i) DTC notifies the Corporation or the Trustee that it is unwilling or unable to continue to act as
depository for this Note in global form or if at any time DTC ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in either such case, a successor depository is not
appointed by the Corporation within 60 calendar days, or (ii) the Corporation executes and delivers to the Trustee a written notification that this Note in global form shall be so exchangeable, or (iii) an Event of Default occurs and is
continuing with respect to this Note in global form. In any such instance, an owner of a beneficial interest in this Note will be entitled to physical delivery in certificated form of Notes equal in principal amount to such beneficial interest and
to have such Notes registered in its name. Unless otherwise set forth above, Notes so issued in certificated form will be issued in authorized denominations only and will be issued in registered form only, without coupons. 
 No service charge shall be made for any such registration of transfer or exchange, but the Corporation may require payment of a sum sufficient to cover
any tax, assessment, or other governmental charge, including, without limitation, any withholding tax, payable in connection therewith. 
 Prior to due presentment of this Note for registration of transfer, the Corporation, the Trustee, the Issuing and Paying Agent, and any agent of the Corporation, the Trustee or any Issuing and Paying Agent may treat the person in whose name
this Note is registered as the owner hereof for all purposes. 
 SECTION 11. Defined Terms. All terms used in this Note which are not
defined herein but are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
 SECTION 12. Governing
Law. THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAWS. 
  

 7 

 ABBREVIATIONS 
 The following abbreviations, when used in the inscription on the face of the within Note, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

			
	TEN COM—	  	as tenants in common
	TEN ENT—	  	as tenants by the entireties
	JT TEN—	  	as joint tenants with right of survivorship and not as tenants in common
	
	UNIF GIFT MIN ACT—
                                     as Custodian
for.                                       
 
	                                        
                  (Cust)
                                        
(Minor)

	                                        
                 Under Uniform Gifts to Minors Act

	
	

 (State) 
 Additional abbreviations may also be used though not in the above list. 
  

 ASSIGNMENT 
 FOR VALUE RECEIVED, the
undersigned hereby sell(s), assign(s) and transfer(s) unto 
 [PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS 
 INCLUDING ZIP CODE OF ASSIGNEE] 
  

	
	  
	
	  
	
	  
	  
 Please Insert Social Security or
Other

	                  Identifying
Number of Assignee:
                                        
                                    
  
 the within Note and all rights thereunder, hereby irrevocably constituting and appointing
                                        
         Attorney to transfer said Note on the books of the Corporation, with full power of substitution in the premises.

	
	Dated:
                                        
                                       
                                        
                                        
         

 NOTICE: The signature to this assignment must correspond with the name as it appears upon the face of the within
Note in every particular, without alteration or enlargement or any change whatever and must be guaranteed. 
  

 8 

 BANK OF AMERICA CORPORATION 
 Medium-Term Senior Note, Series K 
 SUPPLEMENTAL REDEMPTION AMOUNT RIDER

 General 
 This Note is part of a
series of medium-term notes entitled “Medium-Term Notes, Series K” issued under the Indenture, as described in the Prospectus dated April 14, 2004 and Prospectus Supplement dated April 15, 2004 and is designated as the Bank
of America Corporation Return Linked Notes due August 26, 2010, Linked to a Basket of Three Indices. Certain capitalized terms used herein have the meanings ascribed to them in the Prospectus and the Prospectus Supplement. 
 Interest 
 The Notes will not pay any interest.

 Payment at Maturity; Supplemental Redemption Amount 
 At maturity, the Corporation will determine and pay the principal amount of this Note and, under the circumstances described below, a “Supplemental Redemption Amount” calculated by reference to the
performance of a group, or “Basket” of three selected stock indices over the term of this Note. The “Basket Indices” are the three selected stock indices that make up the Basket. The Basket Indices are the S&P 500® Index, the Dow Jones EURO STOXX 50SM Index, and the Nikkei 225 Index. 
 On May 23, 2006, or the “pricing date,” the Corporation priced the Notes. The Basket has an “Initial Basket Level” of 1,000.
Each Basket Index represents a percentage of the Initial Basket Level on the pricing date. For each Basket Index, the Corporation set the “Index Ratio” and the “Index Weight” (as set forth in the table below). The Index Ratio for
each Basket Index was set by (a) multiplying 1,000 by the applicable Index Weight and (b) dividing that product by the closing level of that Basket Index on the pricing date. The result was rounded to the nearest one hundred-thousandth.
The Index Ratio for each Basket Index is subject to change only if certain events or adjustments affect the relevant Basket Index, as described below. 
 The “Basket Level” is the hypothetical value of the Basket that is determined at the close of any Business Day. The Basket Level equals the sum of the products of the closing level and the Index Ratio for
each Basket Index, as determined by the Calculation Agent. The Basket Level will be rounded to the nearest one-hundredth. 
  

 9 

 The following table illustrates the Basket Indices and Index Ratios, as weighted below based on the
closing level of each Basket Index on the pricing date to achieve a Basket Level of 1,000 on that date: 
  

								
	 Basket Index
	  	Closing
Level on
Pricing Date	  	Index
Weight	 	 	Index Ratio
	 S&P 500® Index
	  	1,256.58	  	33.33	%	 	0.26527
	 Dow Jones EURO STOXX 50SM Index
	  	3,620.28	  	33.33	%	 	0.09207
	 Nikkei 225 Index
	  	15,599.20	  	33.33	%	 	0.02137

 After the United States, European, and Japanese stock markets close on the valuation date (as
defined below), the Calculation Agent will determine the Basket Return and any Supplemental Redemption Amount. At maturity, the holder of this Note will be paid the principal amount of this Note and any Supplemental Redemption Amount payable to the
holder of this Note. The Supplemental Redemption Amount, if any, will be based upon the Basket Return, which will be calculated as follows: 
 The “Basket Return” shall equal: 
 Basket Percentage Change x Participation Rate 
 The “Basket Percentage Change” shall equal: 
 Final Basket Level – Initial Basket Level 
 Initial Basket Level 
 The result will be rounded to the nearest ten-thousandth of a decimal place and then expressed as a percentage. 
 The Participation Rate, as established on the pricing date, is equal to 100.00%. The “Final Basket Level” is the Basket Level on
August 20, 2010, or the “valuation date.” 
 If the Basket Return is less than or equal to zero, then the Supplemental
Redemption Amount will equal $0.00. 
 If the Basket Return is greater than zero, then the Supplemental Redemption Amount for each
$1,000 principal amount of this Note will equal the product of: 
 $1,000 x Basket Return 
 This Note is principal protected. If the Basket Return does not exceed zero, the holder of this Note will receive only the principal amount at maturity.

  

 10 

 “Trading Day” means any day, as determined by the Calculation Agent, on which the principal
securities market (or markets) on which the constituent stocks of that Basket Index are open for trading. If the valuation date falls on a day that is not a Trading Day as to one or more Basket Indices, then the valuation date will be postponed to
the first Trading Day thereafter, solely as to the applicable Basket Indices. 
 Event of Default 
 Upon the occurrence of an Event of Default (as defined in the Indenture), the amount that will be due and payable for each $1,000 principal amount of this
Note upon acceleration of this Note will be equal to the $1,000 principal amount only. The holder of this Note will not be entitled to payment of any Supplemental Redemption Amount upon an Event of Default. 
 Market Disruption 
 Each of the following will be a
“Market Disruption Event” if, in the sole opinion of the Calculation Agent, that event materially affects any of the Basket Indices: 
  

	 	•	 	the suspension, material limitation, or absence of the trading of a material number of stocks included in any of the Basket Indices; 

  

	 	•	 	the suspension or material limitation of the trading of stocks on one or more stock exchanges on which stocks included in any of the Basket Indices are quoted;

  

	 	•	 	a breakdown or failure in the price and trade reporting systems of the respective primary markets on which the stocks included in any of the Basket Indices are quoted, as a result
of which the reported trading prices for the affected stocks, during the last one-half hour before the close of trading in that market, are materially inaccurate; or 

  

	 	•	 	the suspension or material limitation of the trading of (a) options or futures relating to any of the Basket Indices on any options or futures exchanges or (b) options or
futures generally. 

 For purposes of determining whether a Market Disruption Event has occurred: 
  

	 	•	 	a limitation on the number of hours or days of trading will not be a Market Disruption Event if it results from an announced change in the regular business hours of the relevant
exchange; 

  

	 	•	 	a limitation on trading imposed by reason of the movements in price exceeding the levels permitted by any relevant exchange will be a Market Disruption Event;

  

	 	•	 	a decision to permanently discontinue trading in the relevant futures or options contracts will not constitute a Market Disruption Event; and 

  

	 	•	 	an absence of trading on an exchange or quotation system will not include any time when that exchange or quotation system is closed for trading under ordinary circumstances.

  

 11 

 If a Market Disruption Event occurs or is continuing with respect to any Basket Index on a day that would
otherwise be the valuation date, then, in order to calculate the Basket Level as of the valuation date, the Calculation Agent instead will use the closing level of the Basket Index on the first Trading Day after that day on which no Market
Disruption Event occurs or is continuing as to that Basket Index. The Calculation Agent will use the closing level for each Basket Index that is not subject to a Market Disruption Event on the valuation date. 
 In no event will the determination of the closing level for any Basket Index subject to a Market Disruption Event be postponed by more than five Business
Days. If any determination as to a Basket Index subject to a Market Disruption Event is postponed to the last possible day, but a Market Disruption Event occurs or is continuing on that day, that day nevertheless will be the valuation date as to
that Basket Index, and the Calculation Agent will make a good faith estimate of the closing level of the Basket Index based upon its assessment of the level of the Basket Index at that time. If any determination of a closing level required to be
made on the valuation date is postponed due to a Market Disruption Event, the Maturity Date for this Note also will be postponed by the same number of Business Days. 
 Discontinuance of the Basket Indices; Alteration of Method of Calculation 
 If the publication of any
of the Basket Indices is discontinued and a successor or substitute index is published that the Calculation Agent determines, in its sole discretion, is comparable to the discontinued Basket Index (the new index being referred to as a
“Successor Index”), then the relevant closing levels of the applicable Basket Index will be determined by reference to the closing level of the Successor Index. 
 If the Calculation Agent selects a Successor Index for any Basket Index, the Calculation Agent immediately will notify the Corporation and the Trustee, and the Trustee will provide written notice of a change to the
holder of this Note within three Business Days of selection. 
 If the publication of a Basket Index or a Successor Index is discontinued,
and the Calculation Agent determines that no Successor Index is available, then the Calculation Agent will notify the Corporation and the Trustee and will calculate the appropriate closing levels. These calculations by the Calculation Agent will be
in accordance with the formula for and method of calculating the applicable Basket Index last in effect prior to that discontinuance. If a Successor Index is selected or the Calculation Agent calculates a level as a substitute for the applicable
Basket Index, that Successor Index or level will be substituted for that Basket Index for all purposes, and the Calculation Agent will make an adjustment to the applicable Index Ratio as it determines to be necessary. 
 If at any time the method of calculating a Basket Index or a Successor Index, or the level of that index, is changed in a material respect, or if a
Basket Index or a Successor Index in any other way is modified so that it does not, in the opinion of the Calculation Agent, fairly represent the level of the Basket Index or the Successor Index had those changes or modifications not been made,
then, from and after that time, the Calculation Agent will notify the Corporation and the 
  

 12 

 Trustee. The Calculation Agent will make those calculations and adjustments as, in the good faith judgment of the
Calculation Agent, may be necessary in order to arrive at a level of a stock index comparable to the applicable Basket Index or the Successor Index, as the case may be, as if those changes or modifications had not been made, and calculate the
closing levels with reference to that Basket Index or the Successor Index, as adjusted. Accordingly, if the method of calculating a Basket Index or a Successor Index is modified so that its level is a fraction of what it would have been if it had
not been modified (e.g., due to a split in an index), then the Calculation Agent will adjust the index in order to arrive at a level of the Basket Index or the Successor Index as if it had not been modified (e.g., as if the split had not occurred).
The Calculation Agent also may determine that no adjustment is required by the modification of the method of calculation. 
 Role of the Calculation Agent

 The Calculation Agent has the sole discretion to make all determinations regarding this Note, including determinations regarding the
Basket Return, the Supplemental Redemption Amount, Market Disruption Events, Successor Indices, Business Days, and Trading Days. Absent manifest error, all determinations of the Calculation Agent will be final and binding on the holder of this Note
and the Corporation, without any liability on the part of the Calculation Agent. 
 The Corporation has initially appointed its affiliate,
Banc of America Securities LLC, as the Calculation Agent, but the Corporation may change the Calculation Agent at any time without notifying the holder of this Note. 
  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]